RoyalVibe Health marketed unapproved medical devices for cancer and other diseases and refused an FDA inspection.
What happened
FDA attempted an inspection at RoyalVibe Health in The Woodlands, TX from June 17, 2022 through July 5, 2022, but the firm did not permit the inspection and did not respond to later requests. FDA also reviewed the firm's websites and found claims that its products diagnose and treat diseases including cancer, Alzheimer's, stroke, arthritis, and type 1 diabetes. FDA determined the products lacked premarket approval or an investigational device exemption and that the firm had not submitted required 510(k) notification or FY2022 registration and listing.
What FDA found
FDA says the products are adulterated because the firm lacks an approved premarket approval application or an approved investigational device exemption for devices intended to diagnose or treat disease.
Section 501(f)(1)(B), 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)FDA says the devices are misbranded because the firm did not notify FDA of its intent to introduce them into commercial distribution as required for 510(k).
Section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)FDA says the firm did not complete annual establishment registration and device listing for fiscal year 2022.
Section 502(o), 21 U.S.C. § 352(o); section 510, 21 U.S.C. § 360FDA says the firm denied or limited an inspection of the establishment where its devices are processed, packed, or held.
Section 501(j), 21 U.S.C. § 351(j)
What FDA wants
Within 15 business days, notify FDA in writing of specific steps taken and planned to correct the violations, prevent recurrence, and provide a timetable if actions will take longer. FDA also asks for a plan to address previously distributed adulterated devices and details on steps taken to remove the products from the US market.
Who should pay attention
- device makers that use disease-treatment claims in consumer marketing
- quality and regulatory teams preparing for FDA inspections
- distributors or retailers selling wellness devices in the US
This is a summary. Read the original letter on fda.gov.